Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1950 1
1951 2
1952 1
1953 2
1954 2
1955 7
1956 1
1961 1
1962 3
1963 3
1964 5
1965 5
1966 4
1967 3
1968 8
1969 10
1970 8
1971 6
1972 9
1973 9
1974 5
1975 7
1976 10
1977 8
1978 2
1979 11
1980 11
1981 15
1982 24
1983 24
1984 18
1985 43
1986 30
1987 16
1988 35
1989 34
1990 42
1991 38
1992 47
1993 51
1994 55
1995 65
1996 64
1997 58
1998 73
1999 71
2000 66
2001 69
2002 98
2003 68
2004 80
2005 80
2006 99
2007 97
2008 111
2009 128
2010 139
2011 171
2012 198
2013 206
2014 217
2015 239
2016 242
2017 261
2018 252
2019 228
2020 228
2021 256
2022 258
2023 254
2024 108

Text availability

Article attribute

Article type

Publication date

Search Results

4,612 results

Results by year

Filters applied: . Clear all
Page 1
Treatment for secondary hyperparathyroidism focusing on parathyroidectomy.
Hiramitsu T, Hasegawa Y, Futamura K, Okada M, Goto N, Narumi S, Watarai Y, Tominaga Y, Ichimori T. Hiramitsu T, et al. Among authors: hasegawa y. Front Endocrinol (Lausanne). 2023 Apr 20;14:1169793. doi: 10.3389/fendo.2023.1169793. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37152972 Free PMC article. Review.
1-Oleoyl-lysophosphatidylethanolamine stimulates RORγt activity in TH17 cells.
Endo Y, Kanno T, Nakajima T, Ikeda K, Taketomi Y, Yokoyama S, Sasamoto S, Asou HK, Miyako K, Hasegawa Y, Kawashima Y, Ohara O, Murakami M, Nakayama T. Endo Y, et al. Among authors: hasegawa y. Sci Immunol. 2023 Aug 4;8(86):eadd4346. doi: 10.1126/sciimmunol.add4346. Epub 2023 Aug 4. Sci Immunol. 2023. PMID: 37540735
Microglia enable cross-modal plasticity by removing inhibitory synapses.
Hashimoto A, Kawamura N, Tarusawa E, Takeda I, Aoyama Y, Ohno N, Inoue M, Kagamiuchi M, Kato D, Matsumoto M, Hasegawa Y, Nabekura J, Schaefer A, Moorhouse AJ, Yagi T, Wake H. Hashimoto A, et al. Among authors: hasegawa y. Cell Rep. 2023 May 30;42(5):112383. doi: 10.1016/j.celrep.2023.112383. Epub 2023 Apr 21. Cell Rep. 2023. PMID: 37086724 Free article.
Oral Exposure to Polystyrene Microplastics of Mice on a Normal or High-Fat Diet and Intestinal and Metabolic Outcomes.
Okamura T, Hamaguchi M, Hasegawa Y, Hashimoto Y, Majima S, Senmaru T, Ushigome E, Nakanishi N, Asano M, Yamazaki M, Sasano R, Nakanishi Y, Seno H, Takano H, Fukui M. Okamura T, et al. Among authors: hasegawa y. Environ Health Perspect. 2023 Feb;131(2):27006. doi: 10.1289/EHP11072. Epub 2023 Feb 22. Environ Health Perspect. 2023. PMID: 36821708 Free PMC article.
Postoperative Adjuvant Anastrozole for 10 or 5 Years in Patients With Hormone Receptor-Positive Breast Cancer: AERAS, a Randomized Multicenter Open-Label Phase III Trial.
Iwase T, Saji S, Iijima K, Higaki K, Ohtani S, Sato Y, Hozumi Y, Hasegawa Y, Yanagita Y, Takei H, Tanaka M, Masuoka H, Tanabe M, Egawa C, Komoike Y, Nakamura T, Ohtsu H, Mukai H. Iwase T, et al. Among authors: hasegawa y. J Clin Oncol. 2023 Jun 20;41(18):3329-3338. doi: 10.1200/JCO.22.00577. Epub 2023 Apr 20. J Clin Oncol. 2023. PMID: 37079878 Clinical Trial.
Dectin-1 signaling on colonic γδ T cells promotes psychosocial stress responses.
Zhu X, Sakamoto S, Ishii C, Smith MD, Ito K, Obayashi M, Unger L, Hasegawa Y, Kurokawa S, Kishimoto T, Li H, Hatano S, Wang TH, Yoshikai Y, Kano SI, Fukuda S, Sanada K, Calabresi PA, Kamiya A. Zhu X, et al. Among authors: hasegawa y. Nat Immunol. 2023 Apr;24(4):625-636. doi: 10.1038/s41590-023-01447-8. Epub 2023 Mar 20. Nat Immunol. 2023. PMID: 36941398 Free PMC article.
Pertuzumab retreatment for HER2-positive advanced breast cancer: A randomized, open-label phase III study (PRECIOUS).
Yamamoto Y, Iwata H, Taira N, Masuda N, Takahashi M, Yoshinami T, Ueno T, Toyama T, Yamanaka T, Takano T, Kashiwaba M, Tsugawa K, Hasegawa Y, Tamura K, Tada H, Hara F, Fujisawa T, Niikura N, Saji S, Morita S, Toi M, Ohno S. Yamamoto Y, et al. Among authors: hasegawa y. Cancer Sci. 2022 Sep;113(9):3169-3179. doi: 10.1111/cas.15474. Epub 2022 Jul 23. Cancer Sci. 2022. PMID: 35754298 Free PMC article. Clinical Trial.
Five-year follow-up of a phase II study of DA-EPOCH-R with high-dose MTX in CD5-positive DLBCL.
Miyazaki K, Sakai R, Iwaki N, Yamamoto G, Murayama K, Nishikori M, Sunami K, Yoshida I, Yano H, Takahashi N, Okamoto A, Munemoto S, Sawazaki A, Suehiro Y, Fukuhara N, Wake A, Arai A, Masaki Y, Toyama K, Yokoyama A, Tsunemine H, Hasegawa Y, Matsumoto K, Yamada T, Nishimura Y, Tamaru S, Asano N, Miyawaki K, Izutsu K, Kinoshita T, Suzuki R, Ohshima K, Kato K, Katayama N, Yamaguchi M. Miyazaki K, et al. Among authors: hasegawa y. Cancer Sci. 2023 Jun;114(6):2689-2691. doi: 10.1111/cas.15784. Epub 2023 Mar 16. Cancer Sci. 2023. PMID: 36929591 Free PMC article. Clinical Trial. No abstract available.
DOCK2 is involved in the host genetics and biology of severe COVID-19.
Namkoong H, Edahiro R, Takano T, Nishihara H, Shirai Y, Sonehara K, Tanaka H, Azekawa S, Mikami Y, Lee H, Hasegawa T, Okudela K, Okuzaki D, Motooka D, Kanai M, Naito T, Yamamoto K, Wang QS, Saiki R, Ishihara R, Matsubara Y, Hamamoto J, Hayashi H, Yoshimura Y, Tachikawa N, Yanagita E, Hyugaji T, Shimizu E, Katayama K, Kato Y, Morita T, Takahashi K, Harada N, Naito T, Hiki M, Matsushita Y, Takagi H, Aoki R, Nakamura A, Harada S, Sasano H, Kabata H, Masaki K, Kamata H, Ikemura S, Chubachi S, Okamori S, Terai H, Morita A, Asakura T, Sasaki J, Morisaki H, Uwamino Y, Nanki K, Uchida S, Uno S, Nishimura T, Ishiguro T, Isono T, Shibata S, Matsui Y, Hosoda C, Takano K, Nishida T, Kobayashi Y, Takaku Y, Takayanagi N, Ueda S, Tada A, Miyawaki M, Yamamoto M, Yoshida E, Hayashi R, Nagasaka T, Arai S, Kaneko Y, Sasaki K, Tagaya E, Kawana M, Arimura K, Takahashi K, Anzai T, Ito S, Endo A, Uchimura Y, Miyazaki Y, Honda T, Tateishi T, Tohda S, Ichimura N, Sonobe K, Sassa CT, Nakajima J, Nakano Y, Nakajima Y, Anan R, Arai R, Kurihara Y, Harada Y, Nishio K, Ueda T, Azuma M, Saito R, Sado T, Miyazaki Y, Sato R, Haruta Y, Nagasaki T, Yasui Y, Hasegawa Y, Mutoh Y, Kimura T, Sato T, Takei R, Hagi… See abstract for full author list ➔ Namkoong H, et al. Among authors: hasegawa y. Nature. 2022 Sep;609(7928):754-760. doi: 10.1038/s41586-022-05163-5. Epub 2022 Aug 8. Nature. 2022. PMID: 35940203 Free PMC article.
Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin®) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study.
Horikawa R, Tanaka T, Hasegawa Y, Yorifuji T, Ng D, Rosenfeld RG, Hoshino Y, Okayama A, Shima D, Gomez R, Pastrak A, Castellanos O. Horikawa R, et al. Among authors: hasegawa y. Horm Res Paediatr. 2022;95(3):275-285. doi: 10.1159/000524600. Epub 2022 Apr 13. Horm Res Paediatr. 2022. PMID: 35417909 Free PMC article. Clinical Trial.
4,612 results